Emory University: Squamous Cell Carcinoma of Head and Neck trials

The registry lists 10 Squamous Cell Carcinoma of Head and Neck studies with Emory University as lead sponsor. 4 are open to participants now and 3 have results posted.

Early Phase 1 1Phase 1 5Phase 2 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck CancerRecruitingNCT06914999Early Phase 1
• TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CancerRecruitingNCT06868433Phase 1
• Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or RadiationRecruitingNCT06662058Not applicable
• Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialRecruitingNCT06636734Phase 2
• Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell CancerCompletedNCT03521570Phase 2Results posted
• Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell CancerActive, not recruitingNCT03468218Phase 2Results posted
• A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck CancerCompletedNCT01283334Phase 1/2Results posted
• VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerActive, not recruitingNCT03690986Phase 1
• Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal CancerWithdrawnNCT03575234Phase 1
• Ganetespib Window of Opportunity Study in Head and Neck CancersTerminatedNCT02334319Phase 1